Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 158

1.

An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis.

Crooke RM, Graham MJ, Lemonidis KM, Whipple CP, Koo S, Perera RJ.

J Lipid Res. 2005 May;46(5):872-84. Epub 2005 Feb 16.

2.

Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.

Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, Tribble DL, Wedel MK, Levin AA, Geary RS.

Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14.

PMID:
19056355
4.

Dietary cholate increases plasma levels of apolipoprotein B in mice by posttranscriptional mechanisms.

Srivastava RA, Averna M, Srivastava N, Pape ME.

Int J Biochem Cell Biol. 2001 Dec;33(12):1215-26.

PMID:
11606258
6.

Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.

Mullick AE, Fu W, Graham MJ, Lee RG, Witchell D, Bell TA, Whipple CP, Crooke RM.

J Lipid Res. 2011 May;52(5):885-96. doi: 10.1194/jlr.M011791. Epub 2011 Feb 22.

7.

Liver LDL receptor mRNA expression is decreased in human ApoB/CETP double transgenic mice and is regulated by diet as well as the cytokine oncostatin M.

Liu J, Zhang YL, Spence MJ, Vestal RE, Wallace PM, Grass DS.

Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2948-54.

8.

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.

Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP, Bhanot S.

Hepatology. 2005 Aug;42(2):362-71.

PMID:
16001399
9.

Hepatic lipase overexpression lowers remnant and LDL levels by a noncatalytic mechanism in LDL receptor-deficient mice.

Dichek HL, Johnson SM, Akeefe H, Lo GT, Sage E, Yap CE, Mahley RW.

J Lipid Res. 2001 Feb;42(2):201-10.

10.

PPARalpha deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins.

Lindén D, Alsterholm M, Wennbo H, Oscarsson J.

J Lipid Res. 2001 Nov;42(11):1831-40.

11.
12.

Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice.

Merki E, Graham MJ, Mullick AE, Miller ER, Crooke RM, Pitas RE, Witztum JL, Tsimikas S.

Circulation. 2008 Aug 12;118(7):743-53. doi: 10.1161/CIRCULATIONAHA.108.786822. Epub 2008 Jul 28.

13.

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B.

Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley JD, Yu RZ, Chuang E, Graham MJ, Crooke RM.

Circulation. 2006 Oct 17;114(16):1729-35. Epub 2006 Oct 9.

14.

Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein.

Lee RG, Fu W, Graham MJ, Mullick AE, Sipe D, Gattis D, Bell TA, Booten S, Crooke RM.

J Lipid Res. 2013 Mar;54(3):602-14. doi: 10.1194/jlr.M029215. Epub 2012 Dec 6.

15.
16.

Antisense apolipoprotein B therapy: where do we stand?

Akdim F, Stroes ES, Kastelein JJ.

Curr Opin Lipidol. 2007 Aug;18(4):397-400. Review.

PMID:
17620855
17.

Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice.

Véniant MM, Withycombe S, Young SG.

Arterioscler Thromb Vasc Biol. 2001 Oct;21(10):1567-70. Review.

18.

Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis.

Zhang YL, Hernandez-Ono A, Siri P, Weisberg S, Conlon D, Graham MJ, Crooke RM, Huang LS, Ginsberg HN.

J Biol Chem. 2006 Dec 8;281(49):37603-15. Epub 2006 Sep 12.

19.

Silencing of mouse hepatic lanosterol 14-alpha demethylase down-regulated plasma low-density lipoprotein cholesterol levels by short-term treatment of siRNA.

Xu B, Wang C, Yang J, Mao G, Zhang C, Liu D, Tai P, Zhou B, Xia G, Zhang M.

Biol Pharm Bull. 2008 Jun;31(6):1182-91.

20.

Mipomersen, an antisense apolipoprotein B synthesis inhibitor.

Bell DA, Hooper AJ, Burnett JR.

Expert Opin Investig Drugs. 2011 Feb;20(2):265-72. doi: 10.1517/13543784.2011.547471. Epub 2011 Jan 6. Review.

PMID:
21210756

Supplemental Content

Support Center